Welcome to our dedicated page for Rein Therapeutics SEC filings (Ticker: RNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rein Therapeutics, Inc. (RNTX) SEC filings page brings together the company’s official U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and registration statements that describe its clinical programs, financing arrangements, and regulatory milestones. These documents provide primary-source detail on how the clinical-stage biopharmaceutical company is advancing therapies for idiopathic pulmonary fibrosis (IPF) and other orphan pulmonary and fibrosis indications.
Among the most relevant filings for RNTX are multiple Form 8-K reports. These include descriptions of the Phase 2 RENEW trial of LTI-03 in IPF, FDA communications regarding a clinical hold and its subsequent resolution, and regulatory authorizations from European agencies for trial sites in the United Kingdom, Germany, and Poland. Other 8-Ks outline the structure and terms of a Pre-Paid Advance Agreement and a Standby Equity Purchase Agreement with an affiliate of Yorkville Advisors, as well as later disclosure that Rein elected to terminate these agreements after taking specified advances and without incurring penalties.
Investors can also review the company’s S-1 registration statement, which summarizes Rein’s business overview, risk factors, and details of the Yorkville standby equity facility, including the number of shares registered for potential resale. Together, these filings explain how Rein describes its lead candidate LTI-03, its second candidate LTI-01 for loculated pleural effusions, and the associated orphan drug and Fast Track designations.
On Stock Titan, AI-powered tools can help interpret lengthy RNTX filings by highlighting key sections on clinical trial design, regulatory status, and financing terms. Users can quickly locate information on material agreements, capital structure changes, and important clinical or regulatory events disclosed in Rein Therapeutics’ SEC documents.
Rein Therapeutics, Inc. is registering 30,000,000 shares of common stock in a primary offering at an assumed price of $1.66 per share, with underwriters holding a 45‑day option for 4,500,000 additional shares. The Nasdaq‑listed company focuses on novel therapies for orphan pulmonary and fibrosis diseases, led by LTI‑03 for idiopathic pulmonary fibrosis, now in the global Phase 2 RENEW trial, with first patient dosed in March 2026 and interim topline data planned for the fourth quarter of 2026.
Rein recently received European orphan drug designation for LTI‑03 and has paused other programs to concentrate resources on this asset. As of December 31, 2025, it reported a net tangible book deficit of approximately $2.91 million and cash of $3.2 million, and raised $5.375 million via unsecured promissory notes in early 2026 that will be repaid from this offering. After the offering and repayment, adjusted net tangible book value is estimated at $0.65 per share, implying about $1.01 per‑share dilution at the assumed price. Management expects existing cash plus offering proceeds to fund operations through at least April 2027, primarily supporting LTI‑03 development and general corporate needs.
Rein Therapeutics, Inc. filed an amendment to its Annual Report for the year ended December 31, 2025 to replace Part III with full disclosures on directors, executive compensation, ownership, related-party transactions, and auditor fees that were previously expected to come from a proxy statement.
The company reports a classified five-member board with separate Chair and CEO roles, and the board considers all directors except CEO Brian Windsor to be independent under Nasdaq and SEC rules. Committees for audit, compensation, and nominating and governance are fully independent and met during 2025.
For 2025, CEO Brian Windsor received total compensation of $882,695, including a $575,000 salary and a $287,500 cash bonus, and holds significant option awards. Interim CFO Timothy Cunningham was paid through a consulting arrangement, receiving $433,940 in 2025. As of March 31, 2026, Windsor beneficially owned 1,057,691 shares (3.6%), while all directors and executive officers as a group held 4.4%. Major holders include Voss Capital at 15.9% and Bios-affiliated entities at 7.1%, before considering additional preferred and warrant overhangs subject to ownership caps.
The filing also outlines an April 2025 private transaction in which Bios-affiliated investors exchanged and bought pre-funded warrants at $1.599 per underlying share, and details a clawback policy, insider trading and anti-hedging restrictions, and 2025 audit fees of $548,225.
Rein Therapeutics, Inc. files its annual report outlining a focused but financially constrained rare-disease lung pipeline. The company is now centered on LTI‑03, an inhaled peptide for idiopathic pulmonary fibrosis, which has Orphan Drug Designation in the U.S. and EU and is in a global Phase 2 RENEW trial with the first patient dosed in March 2026.
Management discloses that existing cash, plus January and February 2026 financing proceeds, are expected to fund operations only into the second quarter of 2026, creating substantial doubt about continuing as a going concern without new capital. Because of these constraints, development of LTI‑01 for loculated pleural effusion and all preclinical programs has been paused indefinitely while resources are prioritized for LTI‑03. The report also highlights a history of net losses and material weaknesses in internal controls that the company is working to remediate, alongside a sizable in‑licensed patent estate around Cav1‑related peptides.
Rein Therapeutics, Inc. entered into securities purchase agreements with three institutional investors for a private placement of unsecured promissory notes. The notes have an aggregate original principal amount of $2,875,000 and were sold for $2,300,000, reflecting a 20% original issue discount instead of cash interest.
The notes mature on the earlier of a future securities financing that brings in at least $10,000,000 of gross proceeds to the company, excluding these notes, or June 30, 2026. The obligations are unsecured, and the agreements include customary representations, warranties and covenants for this type of financing.
Rein Therapeutics, Inc. reported that Manuel C. Alves Aivado, M.D., Ph.D., has resigned from its Board of Directors, effective immediately on February 16, 2026. The company states that his resignation was not due to any disagreement with Rein on its operations, policies, or practices.
The filing confirms Rein Therapeutics remains listed on the Nasdaq Capital Market under the symbol RNTX, and is signed by President and Chief Executive Officer Brian Windsor, Ph.D.
Rein Therapeutics, Inc. (RNTX) has a large shareholder group led by Voss Capital reporting passive ownership on an amended Schedule 13G. As of the close of business on December 31, 2025, Voss Capital and related entities may be deemed to beneficially own 4,468,969 shares of Rein Therapeutics common stock, representing approximately 17.0% of the outstanding shares.
This percentage is based on 26,286,382 shares outstanding as of November 10, 2025, as disclosed in the company’s Form 10-Q. The filing is made on a passive basis, with the reporting persons certifying that the securities are not held for the purpose of changing or influencing control of Rein Therapeutics, apart from activities related to director nominations under the cited rule.
Rein Therapeutics, Inc. entered into a securities purchase agreement with Funicular Funds, LP under which it issued an unsecured promissory note with an original principal amount of $2,500,000 in a private placement. Funicular paid a purchase price of $2,000,000, reflecting a 20% original issue discount instead of cash interest. The note matures on the earlier of the closing of the Company’s next securities financing that raises at least $10,000,000 in gross proceeds (excluding this note) or June 30, 2026. The obligations are unsecured, and the agreement includes customary representations, warranties, covenants and other terms. The note was sold as a private offering under Section 4(a)(2) and Rule 506 of Regulation D.
Rein Therapeutics, Inc. elected to terminate its Pre-Paid Advance Agreement and its Standby Equity Purchase Agreement with YA II PN, Ltd. (Yorkville) on December 11, 2025.
Under the Pre-Paid Advance Agreement, the company had received advances totaling $3 million, with the most recent advance taken on October 23, 2025. The company conducted no sales of its common stock under the Standby Equity Purchase Agreement before termination and reports that no penalties or fees were incurred in connection with ending either arrangement.
Rein Therapeutics, Inc. (RNTX) reported insider buying by a 10% owner group. On 11/14/2025, entities affiliated with Voss Capital reported purchasing 104,183 shares of Rein Therapeutics common stock at a weighted average price of $1.2247 per share, with individual trades ranging from $1.1800 to $1.2500. Following this transaction, Voss Value Master Fund, LP is shown as beneficially owning 926,441 shares indirectly, and Voss Value-Oriented Special Situations Fund, LP is shown as beneficially owning 500,000 shares indirectly. The reporting persons state that, as a group, they beneficially own over 10% of Rein Therapeutics’ outstanding common stock and each disclaims beneficial ownership beyond its pecuniary interest.